Analytikernas rekommendationer, kurser, analyser, diagram
KALLELSE TILL ÅRSSTÄMMA I WESTPAY AB - Yahoo Finance
Media Contact Karen O’Shea, Ph.D. LifeSci Communications koshea@lifescicomms.com 929-469-3860 Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders.
“We recently received Rare Pediatric Disease Designation for TARA-002, our lead product candidate, for the treatment of Lymphatic Malformations. NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs 2020-05-26 · Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease May 26, 2020 08:30 ET | Source Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. Our early pipeline includes programs in genetically defined oncology and immunology indications. Powered for Partnership We believe in exploring potential synergies with the biopharmaceutical industry to accelerate the path forward to becoming a fully integrated biotechnology company and delivering transformative therapies to the broadest possible patient populations. ArTara Therapeutics, Inc. (TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its 2021-03-03 · NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases 2020-05-11 · NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 2020-10-05 · Protara Therapeutics Inc. [TARA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.91.
Analytikernas rekommendationer, kurser, analyser, diagram
Its product pipeline “We are committed to advancing our pipeline of potentially transformative therapies in several areas of high unmet need,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “We recently received Rare Pediatric Disease Designation for TARA-002, our lead product candidate, for the treatment of Lymphatic Malformations. NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a business update. Protara Therapeutics (TARA) is a New York City-based clinical-stage company focused on developing transformative therapies for the treatment of cancer and rare diseases with significant unmet --Protara Therapeutics, Inc., a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, On September 8, 2020, Protara Therapeutics, Inc. (the “Company”) issued a press release entitled “Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications,” a copy of which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.
Aktiekurser för samtliga börslistor - Dagens Industri
The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. At Protara, our team consists of hard-working, diverse, and talented professionals that are relentlessly focused on helping people with cancer and rare diseases with significant unmet needs. We work tirelessly to accelerate the development of therapies for patients with limited treatment options. Located in New York City, we implement a modern and NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that members of the management team will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference being held in a virtual setting on Wednesday, March 17, 2021 at 10:00am ET. Address:Protara Therapeutics, Inc.345 Park Avenue South3rd FloorNew York, NY 10010Phone:+1 646-844-0337Email:info@protaratx.comFollow us on If you have questions, please don’t hesitate to contact us! Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.
Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. 2020-07-24 · About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with rare and specialty diseases who have limited treatment options. “We are committed to advancing our pipeline of potentially transformative therapies in several areas of high unmet need,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “We recently received Rare Pediatric Disease Designation for TARA-002, our lead product candidate, for the treatment of Lymphatic Malformations.
Energibar med dadler
Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its product pipeline “We are committed to advancing our pipeline of potentially transformative therapies in several areas of high unmet need,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “We recently received Rare Pediatric Disease Designation for TARA-002, our lead product candidate, for the treatment of Lymphatic Malformations.
NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for TARA-002 for the treatment of Lymphatic Malformations (LMs). 2021-04-07 · Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company.
Mina utgifter
surface book 3 music production
fastighetsutvecklare lön
antonius cleveland
friseur kreativ wien
Notice of the Annual General Meeting of shareholders of JLT
BRIEF-Protara Therapeutics Receives Rare Pediatric Disease Mar 5, 2021 2021 Insider Inc. and finanzen.net GmbH (Imprint). Protara Therapeutics, Inc. ( NASDAQ:TARA); Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Dec 31, 2020 Aratana Therapeutics, Inc. 11400 Tomahawk Creek Parkway, Suite 340 Protara Therapeutics, Inc. 1 Little West 12th Street New York, NY Looking for a great internship opportunity at Protara Therapeutics, Inc. in New York, NY? Learn more about the Business Development Intern position now! Learn more about our innovative pipeline of potential treatments for recurrent glioblastoma and relapsed small cell lung cancer treatment. Our Development Pipeline. Kintara Therapeutics is focused on developing unique anti-cancer compounds, supported by a strong scientific rationale for Dec 18, 2018 ArTara Therapeutics, a clinical-stage company developing treatments for rare diseases with significant unmet needs, today announced that it Sep 27, 2019 The combined company will focus on advancing ArTara's pipeline of It is expected to operate under the name ArTara Therapeutics and the Propella Therapeutics Inc. (Propella), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), Pipeline | Prothena www.prothena.com/pipeline Protara Therapeutics, Inc. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, Protara Therapeutics, Inc. New York, NY. 22 days ago Mar 21, 2021 (See FLXN stock analysis on TipRanks) Protara Therapeutics (TARA) Staying in the pharma industry, next up we have Protara.
Aktiekurser för samtliga börslistor - Dagens Industri
2020-05-13 · Pipeline Overview TARA-002 * TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, which is approved in Japan and Taiwan Protara Therapeutics is a New York City-based clinical-stage company focused on developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs. Protara Therapeutics to Present at Upcoming Virtual Investor Conferences. NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two 2020-05-13 · NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs Protara’s lead drug candidate, TARA-002, is an investigational cell based therapy based on the broad immunostimulant OK-432, which is approved in Japan and Taiwan for lymphangiomas, including lymphatic malformations (LMs), which are rare, typically congenital, malformations of the lymphatic vasculature. NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for TARA-002 for the treatment of Lymphatic Malformations (LMs). 2021-04-07 · Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs 2020-05-11 · Protara Therapeutics Blaine.Davis@protaratx.com 646-844-0337.
2020-07-24 --ArTara Therapeutics, Inc., a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its name 21 hours ago 2020-10-05 Protara Therapeutics, Inc. Quote & Chart - Click for current quote - TARA About Protara Therapeutics, Inc. (adapted from Protara Therapeutics, Inc. prospectus): They are committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. Our early pipeline includes programs in genetically defined oncology and immunology indications. Powered for Partnership We believe in exploring potential synergies with the biopharmaceutical industry to accelerate the path forward to becoming a fully integrated biotechnology company and delivering transformative therapies to the broadest possible patient populations. Protara Therapeutics is committed to identifying and advancing transformative therapies for people with Using scientific know-how to investigate additional potential of Protara’s pipeline. Köp aktier i Protara Therapeutics Inc - enkelt och billigt hos Avanza Bank.